Literature DB >> 35445373

Establishment and application of a human osteosarcoma U-2OS cell line that can stably express Cas9 protein.

Yonghua Zhou1, Yingjie Li2, Yu Zhang2, Zilin Yi2, Minggui Jiang3.   

Abstract

Osteosarcoma is the most common primary malignant bone tumor, and U-2OS is a common osteosarcoma cell model. The study obtained a human osteosarcoma U-2OS tool cell line which could stably express Cas9 protein, and we reported its production method and application. Firstly, we introduced a Cas9 protein expression gene and an antibiotic screening marker gene through CRISPR/Cas9 system to construct a human osteosarcoma U-2OS tool cell line which could stably express Cas9 protein. Secondly, as the cell line could stably express Cas9 protein, it was only transfected alone a small sgRNA fragment for related gene editing, we then transfected, respectively, a small ETV4 and MALAT1 sgRNA fragment to U-2OS tool cell line for gene editing. Lastly, the Q-PCR results showed that the transcription levels of ETV4 and MALAT1 were significantly decreased, and western blotting result showed that the translation level of ETV4 was significantly decreased, these results indicated that the constructed U-2OS tool cell line could effectively edit protein-coding gene (ETV4) and long non-coding RNA gene (MALAT1). The results of this study also indicated that the constructed U-2OS tool cell line could greatly improve the efficiency of gene editing. Therefore, the genetic engineering cell line provided by the study is of great significance for studying the pathogenesis and regulatory network of osteosarcoma, and for preventing and treating bone tumor as soon as possible.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Application; Cas9 protein; Human osteosarcoma U-2OS

Mesh:

Substances:

Year:  2022        PMID: 35445373     DOI: 10.1007/s11010-022-04434-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.842


  31 in total

1.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease.

Authors:  Seung Woo Cho; Sojung Kim; Jong Min Kim; Jin-Soo Kim
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

2.  Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.

Authors:  Gen Ba; Zhongyan Hua; Ning Xu; Simeng Zhang; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Cell Cycle       Date:  2020-05-13       Impact factor: 4.534

3.  CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.

Authors:  Tang Liu; Zuyun Yan; Yong Liu; Edwin Choy; Francis J Hornicek; Henry Mankin; Zhenfeng Duan
Journal:  Cell Physiol Biochem       Date:  2018-04-16

4.  Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.

Authors:  Z Duan; D E Lamendola; R T Penson; K M Kronish; M V Seiden
Journal:  Cytokine       Date:  2002-03-07       Impact factor: 3.861

5.  Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.

Authors:  Yunfei Liao; Lulu Chen; Yong Feng; Jacson Shen; Yan Gao; Gregory Cote; Edwin Choy; David Harmon; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Oncotarget       Date:  2017-05-02

6.  Efficient CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic manipulation of mammalian neural stem cells.

Authors:  Raul Bardini Bressan; Pooran Singh Dewari; Maria Kalantzaki; Ester Gangoso; Mantas Matjusaitis; Claudia Garcia-Diaz; Carla Blin; Vivien Grant; Harry Bulstrode; Sabine Gogolok; William C Skarnes; Steven M Pollard
Journal:  Development       Date:  2017-01-17       Impact factor: 6.868

Review 7.  Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.

Authors:  Tang Liu; Zhihong Li; Qing Zhang; Karen De Amorim Bernstein; Santiago Lozano-Calderon; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Oncotarget       Date:  2016-12-13

8.  Successful CRISPR/Cas9 mediated homologous recombination in a chicken cell line.

Authors:  Ekaterina Antonova; Olga Glazova; Anna Gaponova; Aykaz Eremyan; Svetlana Zvereva; Natalya Grebenkina; Natalya Volkova; Pavel Volchkov
Journal:  F1000Res       Date:  2018-02-28

9.  FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway.

Authors:  Dunxin Han; Mingming Wang; Zhongkai Yu; Long Yin; Changli Liu; Jianmin Wang; Yongjun Liu; Shengyang Jiang; Zhongwu Ren; Jun Yin
Journal:  Cancer Manag Res       Date:  2019-07-10       Impact factor: 3.989

10.  Engineering large-scale chromosomal deletions by CRISPR-Cas9.

Authors:  Thomas F Eleveld; Chaimaa Bakali; Paul P Eijk; Phylicia Stathi; Lianne E Vriend; Pino J Poddighe; Bauke Ylstra
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.